Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. develops and commercializes medicines for genetic conditions through a decentralized biopharmaceutical model. News for BBIO centers on Attruby/acoramidis, its oral transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM), including clinical data from ATTRibute-CM, commercial updates, Brazil marketing authorization under the BEYONTTRA name, and licensing or commercialization arrangements.
Company updates also cover late-stage genetic-disease programs such as encaleret for autosomal dominant hypocalcemia type 1, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and oral infigratinib for achondroplasia. Recurring financial and corporate items include quarterly results, product revenue trends, capital actions, employee equity inducement grants, investor conference participation, and pipeline regulatory disclosures.
BridgeBio Pharma announced positive results from its Phase 3 ATTRibute-CM study regarding acoramidis treatment for ATTR-CM. The study noted significant increases in serum transthyretin (TTR) levels by Day 28, sustained through Month 30. These increases correlated with reduced all-cause mortality (ACM), cardiovascular mortality (CVM), and cardiovascular-related hospitalization (CVH). Notable improvements were also observed in the composite endpoint of CVM and CVH, with benefits evident as early as Month 3. The company shared plans for the ACT-EARLY trial to prevent ATTR amyloidosis and announced an upcoming investor call on May 29, 2024, to discuss these results.
BridgeBio Pharma will present additional analyses from its Phase 3 ATTRibute-CM study on Acoramidis at the 2024 International Symposium on Amyloidosis (ISA) in Rochester, Minnesota from May 26-30, 2024. The company will host an investor call on May 29, 2024, at 5:30 pm ET to discuss the data, featuring presentations from noted medical experts.
The presentations will highlight Acoramidis' impact on clinical outcomes, including improved survival rates and reduced cardiovascular mortality and hospitalizations in transthyretin amyloid cardiomyopathy (ATTR-CM) patients. Key insights from the trial will also be shared, focusing on quality of life improvements, reduced disease progression, and enhanced biomarkers.
For more details, visit BridgeBio's investor website where all presentations will be accessible.
BridgeBio Pharma, a biopharmaceutical company focusing on genetic diseases and cancers, announced the approval of equity grants to 24 new employees. These grants, totaling 97,557 shares of the Company's common stock, were approved by the compensation committee on May 9, 2024. The vesting schedule for these restricted stock units starts on May 16, 2025, with one-fourth of the shares vesting initially, followed by quarterly vesting of the remaining shares. These inducements, granted under the Amended and Restated 2019 Inducement Equity Plan, comply with Nasdaq Listing Rule 5635(c)(4).
BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, will present at the Bank of America Merrill Lynch Global Healthcare Conference 2024.
The event is scheduled for May 15 at 3:00 pm PT in Las Vegas, NV. The presentation will be accessible via a live webcast on the company's investor relations website, with a replay available for 90 days.
BridgeBio Pharma presented positive results from its Phase 3 ATTRibute-CM study at the ESC Heart Failure Congress 2024. Acoramidis significantly reduced all-cause mortality in the entire study population, with no safety concerns. The treatment also showed benefits in health-related quality of life and NT-proBNP indices. Acoramidis has been submitted for regulatory approval in the US and Europe.
BridgeBio Pharma, Inc. reported significant progress in various programs with positive results in ATTR-CM and LGMD2I/R9 trials. The company secured $1.5 billion in capital, launched BridgeBio Oncology Therapeutics (BBOT), and expects approvals for acoramidis in 2025. Despite positive results, operational costs surged, leading to a net loss for the quarter.
BridgeBio Pharma, Inc. has launched BridgeBio Oncology Therapeutics (BBOT) with $200M in private external capital to accelerate the development of its precision oncology pipeline. The financing was led by Cormorant Asset Management and co-led by Omega Funds, with participation from various investors. BBOT will focus on developing three initial programs targeting RAS and PI3K pathways, with plans to advance into clinical trials in the coming months.
Summary not available.
Summary not available.
Summary not available.